PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib

PD-L1 expression in microvascular endothelial cells predicts the efficacy and side effects of anlotinib

BackgroundImmunotherapy plays a crucial role in the treatment of tumors. However, few studies have investigated the relationship between the expression of Programmed Cell Death Ligand 1 (PD-L1, CD274) in microvascular endothelial cells (MECs), including blood endothelial cells (BECs) and lymphatic e...

Full description

Saved in:

Bibliographic Details
Main Authors:	Yingfang Feng, Yuan Gao, Shaochuan Liu, Tingting Qin, Yan Zhang, Jing Wang, Kai Li
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Oncology
Subjects:	anlotinib PD-L1 microvascular endothelial cells immune checkpoints melanoma
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1544278/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Successful treatment of advanced Birt-Hogg-Dubé syndrome-associated renal cell carcinoma with sarcomatoid dedifferentiation using anlotinib combined with PD-1 inhibitor after first-line therapy failure: a case report
by: Liqi Yi, et al.
Published: (2025-07-01)

Physiological shear stress suppresses apoptosis in human pulmonary microvascular endothelial cells
by: Simin Yan, et al.
Published: (2025-03-01)

Tumor Cavitation with Anlotinib Treatment in Lung Adenocarcinoma
by: Jie Huang, et al.
Published: (2025-05-01)

Long-term efficacy and updated survival outcomes of sintilimab plus anlotinib in patients with PD-L1-positive recurrent or metastatic cervical cancer
by: Jing Liu, et al.
Published: (2025-07-01)

Systematic literature review of real-world evidence on overall survival in cancer patients before and after the approval of anti-PD-(L)1 therapy
by: Dweeti Nayak, et al.
Published: (2025-08-01)

Clinical importance of VEGFC and PD‐L1 co‐expression in lung adenocarcinoma patients
by: Tingting Qin, et al.
Published: (2020-05-01)

Prevalencia de angina microvascular en pacientes del Centro de Investigaciones Médico Quirúrgicas
by: Lázaro Isralys Aldama Pérez, et al.

Anti-PD-1 antibody enhances homeostatic proliferation–induced antitumor immunity during lymphopenia recovery
by: Zike Yang, et al.
Published: (2025-05-01)

Effect of anlotinib as a third‐ or further‐line therapy in advanced non‐small cell lung cancer patients with different histologic types: Subgroup analysis in the ALTER0303 trial
by: Ying Cheng, et al.
Published: (2020-04-01)

PD-1 is conserved from sharks to humans: new insights into PD-1, PD-L1, PD-L2, and SHP-2 evolution
by: Ryohei Kondo, et al.
Published: (2025-05-01)

Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study
by: Yu Hua, et al.
Published: (2025-05-01)

Anlotinib plus camrelizumab and chemotherapy as first-line treatment in patients with advanced esophageal squamous cell carcinoma
by: Mingfang Xu, et al.
Published: (2025-07-01)

The role of markers of endothelial dysfunction in the pathogenesis of coronary microvascular dysfunction in patients with non-obstructive coronary artery disease
by: K. V. Kopeva, et al.
Published: (2024-10-01)

ACTOVEGIN INFLUENCE ON METABOLIC AND VASOMOTOR FUNCTION OF MICROVASCULAR ENDOTHELIAL OF HUMAN SKIN
by: A. A. Fedorovich, et al.
Published: (2016-01-01)

Efficacy and safety of anti-PD-1/PD-L1 antibodies in patients with relapsed refractory diffuse large B-cell lymphoma: A meta-analysis
by: Zhang Jiawen, et al.
Published: (2025-08-01)

PD‐L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy
by: Abul Azad, et al.
Published: (2016-12-01)

Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trialResearch in context
by: Suying Lu, et al.
Published: (2025-06-01)

Real-world efficacy and safety of anlotinib combined with chemotherapy for advanced pancreatic cancer: a retrospective study
by: Zhiyong Li, et al.
Published: (2025-12-01)

Adverse Event Management in Patients with Platinum-Resistant Ovarian Cancer Treated with Niraparib and Anlotinib: Updates from the Phase II, Multi-Center ANNIE Study
by: Deng T, et al.
Published: (2025-07-01)

The endoplasmic reticulum stress-ferroptosis reciprocal signaling orchestrates anti-tumor effect of anlotinib in anaplastic thyroid cancer
by: Yehao Guo, et al.
Published: (2025-08-01)

PD-L1 as a Potential Target in Cancer Therapy (Review)
by: N. N. Andrusova, et al.
Published: (2021-02-01)

The Efficacy of Anlotinib Plus Whole Brain Radiotherapy in Advanced Non‐Small Cell Lung Cancer With Multiple Brain Metastases: A Retrospective Study
by: Lipin Liu, et al.
Published: (2025-01-01)

Coronary Microvascular Dysfunction: Epidemiology, Clinical Presentation, Diagnosis and Treatment
by: E. L. Trisvetova
Published: (2023-05-01)

Evaluation of polymorphism in BCL-2, PD-1, and PD-L1 genes in myelodysplastic neoplasms
by: Bartłomiej Kuszczak, et al.
Published: (2025-01-01)

Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer
by: Jing Nie, et al.
Published: (2025-08-01)

Establishment of an Assay with Ultrahigh Sensitivity for Detecting sEV-Derived PD-L1 as a Serum Biomarker for Lung Cancer—A Pilot Study Using TN-cyclon™
by: Kyo Okita, et al.
Published: (2025-07-01)

Expression of inhibitory receptors PD-1, CTLA-4, and Tim-3 by peripheral T cells during pregnancy
by: E. A. Smetanenko, et al.
Published: (2022-10-01)

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends
by: Talaiti Tuergan, et al.
Published: (2025-12-01)

Immunohistochemical expression of PD-L1 in esophageal carcinoma and its correlation with histopathological features
by: Tarunpreet Saini, et al.
Published: (2024-10-01)

Efficacy of Trimetazidine and Sulodexide in Patients with Microvascular Angina
by: S. A. Boldueva, et al.
Published: (2020-07-01)

Visualization of PD-L1-positive and PD-1-positive immune cell contact in the breast cancer microenvironment
by: A. Yu. Kalinchuk, et al.
Published: (2024-03-01)

Inosine shapes PD-1 blockade responses and synergizes with dual PD-1/CTLA-4 immunotherapy to enhance antitumor immunity
by: Yoichiro Narikawa, et al.
Published: (2025-08-01)

Efficacy and safety of anlotinib combined with 125I seed implantation for iodine-refractory thyroid cancer
by: Zhijun Chen, et al.
Published: (2025-08-01)

Immune checkpoint inhibition perturbs neuro-immune homeostasis and impairs cognitive function
by: Onwodi V. Ifejeokwu, et al.
Published: (2025-07-01)

MicroRNA-155 targets p65 to regulate PD-L1 expression in the early pregnancy endometrium
by: Jinxin Zhang, et al.
Published: (2025-03-01)

Co‐Expression of MHC‐II and ANXA1: Mediators of PD‐1/PD‐L1 Therapy Resistance in Breast Cancer
by: Hao Wang, et al.
Published: (2025-08-01)

The PD-1/PD-L1 pathway and Epstein–Barr virus
by: Hui Wang, et al.
Published: (2025-06-01)

Stereotactic radiosurgery combined with anlotinib for limited brain metastases with perilesional edema in non‐small cell lung cancer: Rvision‐001 study protocol
by: Yuxia Wang, et al.
Published: (2020-05-01)

Exploring the role of TIGIT in patients with Small Cell Lung Cancer as a novel predictor of prognosis and immunotherapy response
by: Li Liu, et al.
Published: (2025-03-01)

Spotlight on nuclear PD-L1 in ovarian cancer chemoresistance: hidden but mighty
by: Meshach Asare-Werehene, et al.
Published: (2025-07-01)